Thymosin Beta-4 5mg
Thymosin Beta-4 – a 43-amino-acid actin-binding protein studied for cell migration and angiogenesis. Price and batch analysis.
49.00 EUR · In stock
This product is intended solely for scientific and research use, as well as for use as a reference standard in HPLC analysis, and is not an approved medicinal product. It is not intended for the diagnosis, treatment or prevention of disease in humans or animals. It has not been approved by the FDA, the EMA or any national regulator. The information on this page is provided for scientific information purposes only and does not constitute medical advice, a recommendation for use, or any claim of clinical efficacy or safety.
Thymosin Beta-4 – what the peptide is
Thymosin beta-4 is a naturally occurring 43-amino-acid protein found in almost all cells of the body. Its highest concentrations have been identified in platelets, white blood cells, and in the fluid released at sites of injury.
Unlike the synthetic fragment TB-500, this product uses the full sequence of the molecule. The two compounds share the actin-binding region but differ in size, which affects their distribution and stability.
The protein is described in the literature as one of the main intracellular regulators of the actin cytoskeleton – the structure that determines cell shape and motility.
Mechanism of action
The molecule binds monomeric G-actin and thereby helps maintain a pool of unpolymerized actin within the cell. This pool allows rapid reorganization of the cytoskeleton when the cell needs to change shape or move.
This function underlies observations related to the migration of endothelial and epithelial cells – a process that precedes the formation of new vessels and the restoration of tissue integrity.
Involvement in the regulation of the inflammatory response has also been described, though this aspect is less well documented than the actin-binding function.
Research data and observations
Observations cover models of corneal, skin, and cardiac muscle injury. Differences in the rate of epithelialization and in the organization of newly formed tissue compared to controls have been reported.
A separate body of work tracks the natural concentrations of the protein in various tissues and their relationship to the stage of the healing process.
Much of the data originates from cell cultures and animal models, which limits direct extrapolation to human conditions.
When interpreting the published data, the difference between preclinical and clinical conditions should be taken into account. Results from cell cultures and animal models describe a mechanism but do not allow quantitative conclusions regarding human conditions.
The dose ranges used in preclinical studies are often not directly translatable due to differences in metabolism between species. This limitation is consistently noted in review articles.
Example calculations
The calculations below are purely mathematical examples illustrating the relationship between the total amount of substance, the solvent volume, and the resulting concentration. They do not constitute a dosing recommendation, administration schedule, or instructions for use.
When reconstituting 5 mg with 2 ml of bacteriostatic water:
The resulting concentration is 2.5 mg/ml, with 0.40 ml containing 1 mg of substance.
Example values:
- 0.1 ml = 0.25 mg
- 0.2 ml = 0.5 mg
- 0.3 ml = 0.75 mg
- 0.4 ml = 1 mg
- 0.5 ml = 1.25 mg
Overview of scientific publications
Thymosin beta-4 was first described in the 1970s and has since been the subject of sustained research interest. The literature on it is more extensive than that on its synthetic fragments.
Review publications note the heterogeneity of the models used, which complicates quantitative summarization of the results.
Safety data from studies
Systematic data on tolerability in humans have not been published in the available literature. The available observations are from preclinical conditions.
The absence of long-term controlled studies is cited as a key limitation in review articles.
A general limitation for compounds in this category is the absence of long-term controlled studies in humans. The available information describes mechanism and short-term observations, not a safety profile for prolonged use.
This product is intended exclusively for research purposes. It is not a food, dietary supplement, or medicinal product and is not intended for the diagnosis, treatment, or prevention of disease.